Q2 Earnings Forecast for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Longeveron in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.18) per share for the quarter, up from their previous forecast of ($0.22). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Longeveron’s Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.74) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.48) EPS.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.33 million. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%.

A number of other equities research analysts have also recently commented on LGVN. Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. Maxim Group downgraded Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Wall Street Zen downgraded Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.50.

Longeveron Stock Up 0.8%

Shares of Longeveron stock opened at $0.68 on Tuesday. The firm has a fifty day moving average of $0.94 and a two-hundred day moving average of $0.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.88 and a current ratio of 3.88. The company has a market cap of $15.73 million, a P/E ratio of -0.60 and a beta of -0.31. Longeveron has a one year low of $0.48 and a one year high of $1.80.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC purchased a new position in shares of Longeveron Inc. (NASDAQ:LGVN) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron at the end of the most recent reporting period. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.